Treating prostate cancer with anti-ErbB2 antibodies
US7041292B1 · kind B1 · utility
53Cited by
77References
14Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jun 23, 2000 |
| Grant date | May 9, 2006 |
| Priority date | — |
| Expiry date | Jun 15, 2021 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S424/801
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present application discloses treatment of prostate cancer with anti-ErbB2 antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.